Pathologic staging of melanoma

Seminars in Oncology

Volumn 29, Issue 4, 2002, Pages 370-381

  Ruiter, Dirk J ^a,b,c,d   Spatz, Alain ^a,b,c,d   Van Den Oord, Joost J ^a,b,c,d   Cook, Martin G ^a,b,c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; TISSUE DISTRIBUTION; ULCEROGENESIS;

EID: 0036333832     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34116     Document Type: Article

References (86)

1. A New Americal Joint Committee on Cancer staging system for cutaneous melanoma
2. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
3. The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group
4. Microstaging of melanoma
5. Model predicting survival in stage I melanoma based on tumor progression
6. Malignant melanoma. A clinicopathological analysis of the criteria for diagnosis and prognosis
7. Cutaneous melanoma: Ulceration as a prognostic sign
8. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia
9. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma
10. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)
11. Cutaneous melanoma: Prognosis and treatment results worldwide
12. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm)
13. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
14. The prognostic significance of ulceration of cutaneous melanoma
15. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
16. Prognostic histopathological factors in malignant melanoma
17. Predicting survival and recurrence in localized melanoma: A multivariate approach
18. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma
19. Ulceration and prognosis in cutaneous malignant melanoma
20. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
21. Prognostic factors for stage I melanoma of the skin: A review
22. A long-term analysis of 620 patients with malignant melanoma at a major referral center
23. Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma
24. Prognosis of thick cutaneous melanoma
25. Assessment of prognosis in patients with malignant melanoma
26. Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation
27. Breslow thickness and clark level in melanoma: Support for including level in pathology reports and in American Joint Committee on Cancer Staging
28. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations
29. Prognostic factors in invasive cutaneous malignant melanoma: A population-based study and review
30. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma
31. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma
32. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters
33. High tPA-expression in primary melanoma of the limb correlates with good prognosis
34. Predicting fiveyear outcome for patients with cutaneous melanoma in a population-based study
35. Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982
36. Clinical and histologic trends of melanoma
37. Trends in turnout characteristics and survival of malignant melanoma 1960-84: A population-based study in Sweden
38. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma
39. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: Correlation with newly proposed staging system
40. Do patients with tumor-positive sentinel nodes constitute a homogeneous group?
41. The EORTC Melanoma Group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma
42. Malignant melanoma. A multivariate analysis of prognostic factors
43. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?
44. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma
45. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm)
46. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group
47. Observer variation in histological classification of cutaneous malignant melanoma
48. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions
49. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia
50. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma
51. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions
52. Expression of c-myc oncoprotein represents a new prognosticmarker in cutaneous melanoma
53. Autocrine and paracrine roles for growth factors in melanoma
54. Melanomastroma interactions. Structural and functional aspects
55. Molecular staging of malignant melanoma: Correlation with clinical outcome
56. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma
57. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood
58. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma
59. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR
60. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma
61. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence
62. Progression-related expression of beta 3 integrin in melanomas and nevi
63. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma
64. Matrix metalloproteinases in human melanoma
65. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma
66. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression
67. Micropthalmia transcription factor: A new prognostic marker in intermediatethickness cutaneous malignant melanoma
68. CD40 is a prognostic marker in primary cutaneous malignant melanoma
69. Analysis of N-and K-ras mutations in the distinctive tumor progression phases of malignant melanoma
70. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis
71. The sentinel node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma
72. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma
73. Examination of regional lymph nodes by sentinel node biopsy and mlecular analysis provides new staging facilities in primary cutaneous melanoma
74. Sentinel node biopsies in melanoma patients: A protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of TyrPCR
75. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. A immunohistological study
76. Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes
77. The detection of micrometastases in melanoma sentinel nodes by step-sectioning and immunohistochemical staining
78. Molecular staging of malignant melanoma. Correlation with clinical outcome
79. Sentinel lymph node biopsy for melanoma
80. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes
81. Sentinel node biopsy in melanoma
82. Pathologic examination of the sentinel lymph node in malignant melanoma
83. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence
84. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes
85. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients
86. The tumor biology of melanoma nodal metastases